



UNITED STATES PATENT AND TRADEMARK OFFICE

CH
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,436	08/16/2005	Kazuo Kobayashi	081356-0224	8917
22428	7590	01/24/2008	EXAMINER	
FOLEY AND LARDNER LLP			VOGEL, NANCY S	
SUITE 500			ART UNIT	PAPER NUMBER
3000 K STREET NW			1636	
WASHINGTON, DC 20007			MAIL DATE	DELIVERY MODE
			01/24/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/511,436	KOBAYASHI ET AL.
	Examiner Nancy T. Vogel	Art Unit 1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-122 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-122 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date: _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date: _____	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

The following is a restriction requirement which supercedes the previous requirement, mailed 10/9/07. The examiner apologizes for any inconvenience. Applicants may phone the examiner with an election if desired.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, and 94-96 and 108-114, drawn to method for producing a methylotroph yeast that is capable of producing a mammalian-type sugar chain.

Group II, claim(s) 26-30, drawn to inventions pertaining to an orotidine 5' phosphate decarboxylase (URA3) gene.

Group III, claim(s) 31-35, drawn to inventions pertaining to a phosphoribosyl-amino-imidazole synthase (ADE1) gene.

Group IV, claim(s) 36-40, drawn to inventions pertaining to an imidazole-glycerol-phosphate dehydratase (HIS3) gene.

Group V, claim(s) 41-45, drawn to inventions pertaining to a 3-isopropylmalate dehydrogenase (LEU2) gene .

Group VI, claim(s) 46-49, drawn to inventions pertaining to an alpha-1,6-mannosyltransferase (OCH1) gene.

Group VII, claim(s) 50-53, drawn to inventions pertaining to a PEP4 gene.

Group VIII, claim(s) 54-57, drawn to inventions pertaining to a proteinase B (PRB1) gene.

Group IX, claim(s) 58-69, drawn to inventions pertaining to a YPS1 gene.

Group X, claim(s) 70-73, drawn to inventions pertaining to a KTR1 gene.

Group XI, claim(s) 74-77, drawn to inventions pertaining to an MNN9 gene.

Group XII, claim(s) 78-85, drawn to inventions pertaining to an alcohol oxidase (AOX) gene.

Group XIII, claim(s) 86-93, drawn to inventions pertaining to a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.

The inventions listed as Groups I-XIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of each group is different, since it is in each group, the structure of the recited gene or protein encoding sequence, and/or the microorganism comprising said gene, and/or the microorganism lacking said gene, and/or the method of using or making said microorganism, said genes having different structures and functions.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

For Group I, the species are the URA3 gene (SEQ ID NO:15), ADE1 gene (SEQ ID NO:27), HIS3 gene (SEQ ID NO:99), LEU2 gene (SEQ ID NO:107), OCH1 gene

(SEQ ID NO:42), PEP4 gene (SEQ ID NO:51), PRB1 gene (SEQ ID NO:57), KTR1 gene (SEQ ID NO:63), YPS1 gene (SEQ ID NO:115).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

Claim 96 comprises the method of 94 or 95 in which a further step of disrupting at least one of the URA3, DE1, HIS 3, LEU2 gene is disrupted. One gene should be selected. Claim 108 comprises a method for producing a mutant strain comprising disrupting numerous genes. One gene should be selected.

The following claim(s) are generic: 1-4, 94-96, 108-114.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the special technical feature of each species is the particular gene which is deleted, and each gene has a separate and different chemical structure and function. Furthermore, the search for all of the recited genes would exceed the capacity of the search system and is burdensome.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Claims 5-25, 69, 97-107 and 115-122 are in improper form because a multiple dependent claim may not depend from another multiple dependent claim. See MPEP 608.01(n). Accordingly, the claims have not been assigned to restriction groups.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy T. Vogel whose telephone number is (571) 272-0780. The examiner can normally be reached on 7:00 - 3:30, Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


NANCY VOGEL
PRIMARY EXAMINER

NV
1/16/08